Increasing Prevalence of Neurological Disorders
The rising prevalence of neurological disorders is one of the primary factors driving the neurostimulation devices market. In 2013, as per the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC), 84,767 people had died due to Alzheimer’s disease. Each year nearly, 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. In emerging markets such as India, nearly 30 million people suffer from neurological disorders with a prevalence of around 2,400 patients per 10,000 population. Thus, a high number of patients suffering from neurological diseases needs hospitalizations, worldwide, which raises the demand for early diagnosis of these diseases driving this market.
Other factors driving this market are the rising demand for minimally invasive technologies and the expanding number of elderly patients with neurological disorders seeking technological advancements in neurological devices.
High Cost of Neurological Diseases Treatment
Annually, a large part of healthcare expenditure goes to the neurological disease treatment. It is highly expensive for the public in developed countries and more so in the emerging market. Over one-third population of the United States suffer from neurological diseases, which is close to a 100 million, and posts enormous financial strain over the healthcare system, as nearly USD 800 billion annual costs goes into its treatment. In emerging markets such South Asian countries, the financial burden for the treatment of neurological conditions is further misbalanced compared to the patients require the treatment. Thus, it is one of primary factor impeding this market.
Another major factor impeding this market is the lack of skilled healthcare professionals in neurology.
Asia-Pacific Holds Vast Growth Opportunities
The Asia-Pacific region is expected to show fastest growth rate over the period, 2018 to 2023 which should provide huge investment opportunities for the neurostimulation devices companies in countries, such as India, China, and Japan. In recent years, high economic growth has been observed in these countries, with a vast diversified patient pool. These countries have observed an improving healthcare facilities largely due to involvement and expansion of private sectors companies in healthcare collaborating with multinational healthcare organizations to provide better treatment, giving rise to multiple growth prospects.
The North America region is expected to dominate the market in the forecast period due to the well-developed healthcare infrastructure, healthcare facilities, and high adoption of new technologies.
Key Developments in the Market
- February 2018 - Synergia Medical SA raised EUR 8.1 million in Series A funding for its novel opto-electronic neurostimulation device.
- January 2018 - Helius Medical Technologies, Inc. partnered with Key Tronic Corp. to manufacture portable neuromodulation stimulator (PoNS).
Reasons to Purchase the Repor:t
- Current and future of neurostimulation devices market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements. Please contact us for more information.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Rising Prevalence of Neurological Disorders
6.1.2 Rising Demand of Minimally Invasive Technologies
6.1.3 Rising Number of Elderly Patients with Neurological Disorders
6.1.4 Development of Technologically Advanced Neurological Devices
6.2.1 High Cost of Neurological Diseases Treatment
6.2.2 Lack of Skilled Healthcare Professionals in Neurology
6.4 Key Challenges
7. Market Segmentation
7.1 By Devices Type
7.1.1 Implantable Devices
220.127.116.11 Vagus Nerve Stimulators
18.104.22.168 Spinal Cord Stimulators
22.214.171.124 Deep Brain Stimulators
126.96.36.199 Gastric Electric Stimulators
7.1.2 External Devices
188.8.131.52 Transcranial Magnetic Stimulation (TMS)
184.108.40.206 Transcutaneous Electrical Nerve Stimulation (TENS)
7.2 By Application
7.2.1 Parkinson's Disease
7.2.5 Pain Management
7.2.6 Others Indications
7.3 By Geography
7.3.1 North America
220.127.116.11 United States
18.104.22.168 Rest of North America
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
7.3.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
7.3.5 South America
22.214.171.124 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Bayer Corporation
9.3 Boston Scientific Corporation
9.4 Cyberonics, Inc.
9.5 DePuy Synthes
9.6 Interpace Diagnostics LLC
9.8 NeuroPace, Inc.
9.9 Nevro Corp
9.10 Synapse Biomedical, Inc.
*List not Exhaustive
10. Future of the Market